| Name | N-[(1S)-2-[[(7S)-6,7-Dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluorobutanamide |
|---|---|
| Synonyms |
4-trifluoro-N-((S)-1-(((S)-5-(2-hydroxyethyl)-6-oxo-6
3-b]azepin-7-yl)amino)-1-oxopropan-2-yl)butanamide 4,4,4-Trifluoro-N-[(2S)-1-{[(7S)-5-(2-hydroxyethyl)-6-oxo-6,7-dihydro-5H-pyrido[3,2-a][3]benzazepin-7-yl]amino}-1-oxo-2-propanyl]butanamide Butanamide, N-[(1S)-2-[[(7S)-6,7-dihydro-5-(2-hydroxyethyl)-6-oxo-5H-pyrido[3,2-a][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]-4,4,4-trifluoro- UNII:923X28214S Crenigacestat LY3039478 LY-3039478 |
| Description | Crenigacestat (LY3039478) is a novel and potent Notch inhibitor. |
|---|---|
| Related Catalog | |
| In Vivo | In a xenograft tumor model, Crenigacestat (LY3039478) inhibit N1ICD cleavage and expression of Notch-regulated genes in the tumor microenvironment. Crenigacestat (LY3039478) is being investigated in Phase I. |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 818.7±65.0 °C at 760 mmHg |
| Molecular Formula | C22H23F3N4O4 |
| Molecular Weight | 464.438 |
| Flash Point | 448.9±34.3 °C |
| Exact Mass | 464.167145 |
| PSA | 111.63000 |
| LogP | 1.83 |
| Vapour Pressure | 0.0±3.1 mmHg at 25°C |
| Index of Refraction | 1.594 |
| Storage condition | -20℃ |